Publicacions en què col·labora amb OMAR CAULI (11)

2014

  1. Blocking NMDA receptors delays death in rats with acute liver failure by dual protective mechanisms in kidney and brain

    NeuroMolecular Medicine, Vol. 16, Núm. 2, pp. 360-375

  2. Non invasive blood flow measurement in cerebellum detects minimal hepatic encephalopathy earlier than psychometric tests

    World Journal of Gastroenterology, Vol. 20, Núm. 33, pp. 11815-11825

2013

  1. Chronic hyperammonemia, glutamatergic neurotransmission and neurological alterations

    Metabolic Brain Disease

2011

  1. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis

    American Journal of Gastroenterology, Vol. 106, Núm. 9, pp. 1629-1637

2010

  1. Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications

    Metabolic Brain Disease

2009

  1. Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy

    Metabolic Brain Disease, Vol. 24, Núm. 1, pp. 69-80

  2. Mechanisms of cognitive alterations in hyperammonemia and hepatic encephalopathy: Therapeutical implications

    Neurochemistry International, Vol. 55, Núm. 1-3, pp. 106-112

2007

  1. NMDA receptors in hyperammonemia and hepatic encephalopathy

    Metabolic Brain Disease

  2. The function of the glutamate-nitric oxide-cGMP pathway in brain in vivo and learning ability decrease in parallel in mature compared with young rats

    Learning and Memory, Vol. 14, Núm. 4, pp. 254-258

2006

  1. <i>N</i>-methyl-D-aspartate receptors in hyperammonaemia and hepatic encephalopathy

    HEPATIC ENCEPHALOPATHY AND NITROGEN METABOLISM

  2. Role of extracellular cGMP and of hyperammonemia in the impairment of learning in rats with chronic hepatic failure. Therapeutic implications

    Neurochemistry International, Vol. 48, Núm. 6-7, pp. 441-446